

Ad of
#12



Docket No. 3816-4000

Express Mail #EK 784 976 278US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant(s): Peter Kufer, et al.

Group Art Unit: 1646

MAY 25 2001

Serial No.: 09/403,107

Examiner: Gerald Ewoldt, Ph.D.

TECH CENTER 1600/2900

Filed: October 14, 1999

For: NOVEL METHOD FOR THE PRODUCTION OF ANTIHUMAN ANTIGEN RECEPTORS AND USES THEREOF

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application.

☒ No additional fee is required.

☐ The additional fee has been calculated as shown below:

CLAIMS AS AMENDED

	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Extra	Rate	Additional Fee
Total Claims*	39 -	89	0	\$18.00/ \$9.00	\$ 0
Independent Claims	3 -	3	0	\$80.00/ \$40.00	\$ 0
Multiple Dependent Claims	(If claims added by amendment include Multiple Dependent Claim(s) and there was no Multiple Dependent Claim(s) in application before amendment add \$270.00 to additional fee (\$135 for small entity).				\$ 0
TOTAL					\$ 0

*Includes all independent and single dependent claims and all claims referred to in multiple dependent claims. See 37 C.F.R. §1.75(c).

☐ Small entity status is or has been claimed.


Reduced Fees Under 37 C.F.R. §1.9(f) paid herewith \$_____

- ☐ Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for filing this amendment, including all fees pursuant to 37 CFR §1.17 for its timely consideration, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3816-4000. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☐ _____ Pages Sequence Listing
- ☐ _____ Computer disk(s) containing substitute Sequence Listing
- ☐ Statement under 37 C.F.R. §1.825(b) that the computer and paper copies of the substitute Sequence Listing are the same.
- ☐ A check in the amount of \$_____ to cover the filing fee is attached.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: May 22, 2001

By: _____


Maria C.H. Lin
Registration No. 29,323

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



05-23-01

GAC 1646

Docket No. 3816-4000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 25 2001

Applicant(s): Peter Kifer et al

Group Art Unit: 1646

Serial No.: 09/403,107

Examiner: Gerald Ewoldt, Ph.D.

Filed: October 14, 1999

For: Novel Method for the Production of Antihuman Antigen Receptors and Uses Thereof

TECH CENTER 1600/2900

EXPRESS MAIL CERTIFICATEExpress Mail Label No.: EK 784 876 278USDate of Deposit: May 22, 2001


I hereby certify that the following attached paper(s) and/or fee

1. Supplemental Response to Restriction Requirement;
2. Appendix A -Clean copy of claim
3. Amendment Fee Transmittal; and
4. Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

F. Garcia

(Typed or printed name of person mailing papers(s) and/or fee)


(Signature of person mailing paper(s) and/or fee)Correspondence Address:

MORGAN & FINNEGAN, L.L.P.

345 Park Avenue

New York, NY 10154-0053

(212) 758-4800 Telephone

(212) 751-6849 Facsimile



12
D
5/29/01
PATENT

Docket No. 3816-4000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Peter Kufer, et al
Serial No : 09/403,107
Filed : October 14, 1999
For : NOVEL METHOD FOR THE PRODUCTION OF ANTIHUMAN
ANTIGEN RECEPTORS AND USES THEREOF
Group Art Unit : 1646
Examiner : Gerald Ewoldt, Ph.D.

RECEIVED

MAY 25 2001

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Attention: Non-Fee Amendment

**SUPPLEMENTAL RESPONSE TO
RESTRICTION REQUIREMENT**

Sir:

This is to supplement the response to the office action dated March 27, 2001 for which a response was filed April 24, 2001.

Please replace amended claim 22 with the following::

22. (Twice Amended). The anti-human antigen receptor according to claim 18 wherein said VH is [selected from the group consisting of] nucleotides 1 to [3]381 of Seq. ID NO: 143 [and nucleotides 1 to 339 of Seq. ID No.: 145] and said VL chain is [selected from the group consisting of] nucleotides 1 to 321 of Seq. ID No.: 141 [and nucleotides 1 to 321 of Seq. ID No.: 147].

REMARKS

Amended Claim 22 was submitted on April 24, 2001. Unfortunately, due to a computer glitch, the third line of the amended claim was omitted. Please replace with the above and consider it with the remainder of the amendment and response filed on April 24, 2001 requested.